Related Experiment Video
Updated: Jan 24, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Deciphering the CAF‑LCN2 axis: Key to overcoming anti‑PD‑L1 immunotherapy resistance in lung cancer
Dan Xiao1, Jing Yang2, Jianying Zhou1
1Department of Thoracic Oncology, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Key Laboratory of Oncology, Jiangxi Cancer Hospital and Institute, Nanchang, Jiangxi 330029, P.R. China.
Abstract:
Lung cancer is a highly aggressive malignancy associated with a high global mortality rate. Immunotherapy, particularly anti‑programmed cell death protein 1 (PD‑1) therapy, has offered new hope for patients; however, therapeutic resistance remains a major obstacle to clinical success. In the present study, single‑cell RNA sequencing was utilized to investigate the molecular characteristics of lung cancer and to elucidate the mechanisms underlying resistance to anti‑PD‑1 immunotherapy. Cancer‑associated fibroblasts (CAFs) were identified as key contributors to immune resistance. Functional assays, including CCK‑8, EdU, TUNEL and Transwell experiments, demonstrated that CAFs regulated the expression of lipocalin 2 (LCN2) in lung cancer cells, and elevated LCN2 levels were found to promote resistance to immunotherapy, as well as to enhance cellular proliferation and invasion. The effects of LCN2 on tumor growth, invasion, immune infiltration and ferroptosis were further validated by molecular and histological analyses. The results showed that silencing LCN2 induced ferroptosis in lung cancer cells, resulting in increased sensitivity to anti‑PD‑1 therapy, suppressed tumor growth and reduced invasiveness. These findings highlight the critical role of the CAF‑LCN2 axis in mediating resistance to anti‑PD‑1 immunotherapy and suggest that targeting this pathway may represent a promising strategy to enhance treatment efficacy in lung cancer.
Insights
Cancer-associated fibroblasts promote lung cancer immunotherapy resistance via lipocalin 2. Targeting this CAF-LCN2 axis can enhance anti-PD-1 therapy efficacy by inducing ferroptosis and suppressing tumor growth.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Lung cancer has a high mortality rate, and resistance to immunotherapy, such as anti-programmed cell death protein 1 (PD-1) therapy, is a significant clinical challenge.
- Understanding the molecular mechanisms of therapeutic resistance is crucial for improving patient outcomes.
Purpose of the Study:
- To investigate the molecular characteristics of lung cancer and identify mechanisms of resistance to anti-PD-1 immunotherapy.
- To elucidate the role of cancer-associated fibroblasts (CAFs) and lipocalin 2 (LCN2) in mediating immunotherapy resistance.
Main Methods:
- Single-cell RNA sequencing was employed to analyze lung cancer molecular profiles.
- Functional assays (CCK-8, EdU, TUNEL, Transwell) and molecular/histological analyses were performed.
- LCN2 expression and its impact on tumor growth, invasion, immune infiltration, and ferroptosis were assessed.
Main Results:
- Cancer-associated fibroblasts (CAFs) were identified as key players in promoting immune resistance.
- CAFs regulate lipocalin 2 (LCN2) expression in lung cancer cells; elevated LCN2 enhances proliferation, invasion, and immunotherapy resistance.
- Silencing LCN2 induced ferroptosis in lung cancer cells, increasing sensitivity to anti-PD-1 therapy, suppressing tumor growth, and reducing invasiveness.
Conclusions:
- The cancer-associated fibroblast (CAF)-lipocalin 2 (LCN2) axis is critical in mediating resistance to anti-PD-1 immunotherapy in lung cancer.
- Targeting the CAF-LCN2 pathway, potentially by inducing ferroptosis, offers a promising strategy to overcome therapeutic resistance and improve anti-PD-1 treatment efficacy.
More Related Videos
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
Treatment Resistant Cancers
Tumor Immunotherapy
Hypothalamic-Pituitary Axis
Key Techniques in Microbiology
Key Elements for Plant Nutrition
PD Controller: Design
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...